ΔE1 and high-capacity adenoviral vectors expressing full-length codon-optimized merozoite surface protein 1 for vaccination against Plasmodium falciparum

J Gene Med. 2011 Dec;13(12):670-9. doi: 10.1002/jgm.1627.

Abstract

Background: The merozoite surface protein (MSP)-1 of Plasmodium falciparum, the causative agent of malaria tropica, is considered to be a promising vaccine candidate. Although its stable cloning and expression has been difficult in the past, adenoviral vectors expressing the complex protein are described in the present study.

Methods: Codon-optimized msp-1 was used to construct a set of first generation (ΔE1Ad) and high-capacity adenovirus (HC-Ad) vectors, and cellular and humoral immune responses induced by the vectors were characterized in detail in mice.

Results: Generation of stable ΔE1Ad and HC-Ad vectors expressing full-length MSP-1 and their production to high vector titers was found to be feasible. Epitope identification and analysis of frequencies of specific CD8 T-cells revealed that MSP-1 expressing HC-Ad vectors induced higher frequencies of interferon-γ + CD8 T-cells than ΔE1 vectors. Irrespective of the vector format, higher titers of MSP-1 specific antibodies were generated by Ad vectors expressing MSP-1 from a chicken β-actin (CAG) promoter comprising the cytomegalovirus early enhancer element and the chicken β-actin promoter.

Conclusions: The findings of the present study suggest that Ad vectors expressing full-length codon-optimized MSP-1 are promising candidate vaccines against P. falciparum infections. Use of the HC-Ad vector type for delivery, as well as the CAG promoter to control MSP-1 expression, may further increase the efficacy of this vaccine candidate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenovirus Vaccines* / genetics
  • Adenovirus Vaccines* / immunology
  • Adenovirus Vaccines* / therapeutic use
  • Animals
  • Antibody Specificity
  • CD8-Positive T-Lymphocytes / immunology
  • Codon / genetics
  • Female
  • Genetic Vectors
  • Humans
  • Interferon-gamma / metabolism
  • Malaria, Falciparum / genetics
  • Malaria, Falciparum / therapy*
  • Merozoite Surface Protein 1* / genetics
  • Merozoite Surface Protein 1* / immunology
  • Merozoite Surface Protein 1* / therapeutic use
  • Mice
  • Mice, Inbred BALB C
  • Plasmodium falciparum* / immunology
  • Plasmodium falciparum* / pathogenicity
  • Promoter Regions, Genetic

Substances

  • Adenovirus Vaccines
  • Codon
  • Merozoite Surface Protein 1
  • Interferon-gamma